Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (11): 883-892.DOI: 10.5246/jcps.2022.11.075
• Original articles • Previous Articles Next Articles
Yuehua Liu#, Zhangqin Xue#, Jianming Wei, Ruomeng Wei, Baodong Yin, Aiqin Liu*()
Received:
2022-01-11
Revised:
2022-04-26
Accepted:
2022-05-09
Online:
2022-11-30
Published:
2022-11-30
Contact:
Aiqin Liu
About author:
Supporting:
Yuehua Liu, Zhangqin Xue, Jianming Wei, Ruomeng Wei, Baodong Yin, Aiqin Liu. Study on drug synthesis and activity of sodium olpadronate[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 883-892.
[1] |
Letarouilly, J.G.; Broux, O.; Clabaut, A. New insights into the epigenetics of osteoporosis. Genomics. 2019, 111, 793–798.
|
[2] |
Cauley, J.A. Public health impact of osteoporosis. J. Gerontol. A Biol. Sci. Med. Sci. 2013, 68, 1243–1251.
|
[3] |
Baron, R.; Ferrari, S.; Russell, R.G.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011, 48, 677–692.
|
[4] |
McClung, M.; Harris, S.T.; Miller, P.D.; Bauer, D.C.; Davison, K.S.; Dian, L.; Hanley, D.A.; Kendler, D.L.; Yuen, C.K.; Lewiecki, E.M. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med. 2013, 126, 13–20.
|
[5] |
Ebetino, F.H.; Hogan, A.M.L.; Sun, S.T.; Tsoumpra, M.K.; Duan, X.C.; Triffitt, J.T.; Kwaasi, A.A.; Dunford, J.E.; Barnett, B.L.; Oppermann, U.; Lundy, M.W.; Boyde, A.; Kashemirov, B.A.; McKenna, C.E.; Russell, R.G.G. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011, 49, 20–33.
|
[6] |
Yavropoulou, M.P.; Makras, P.; Anastasilakis, A.D. Bazedoxifene for the treatment of osteoporosis. Expert Opin. Pharmacother. 2019, 20, 1201–1210.
|
[7] |
Martinkovich, S.; Shah, D.; Planey, S.L.; Arnott, J.A. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin. Interv. Aging. 2014, 9, 1437–1452.
|
[8] |
Hadji, P. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric. 2012, 15, 513–523.
|
[9] |
Bock, O.; Felsenberg, D. Bisphosphonates in the management of postmenopausal osteoporosis: optimizing efficacy in clinical practice. Clin. Interv. Aging. 2008, 3, 279–297.
|
[10] |
Russell, R.G.G. Bisphosphonates: the first 40 years. Bone. 2011, 49, 2–19.
|
[11] |
Sun, M.; Iqbal, J.; Singh, S.; Sun, L.; Zaidi, M. The crossover of bisphosphonates to cancer therapy. Ann. NY Acad. Sci. 2010, 1211, 107–112.
|
[12] |
Coleman, R.; Body, J.J.; Aapro, M.; Hadji, P.; Herrstedt, J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2014, 25, iii124–iii137.
|
[13] |
Rogers, M.J.; Frith, J.C.; Luckman, S.P.; Coxon, F.P.; Benford, H.L.; M̈onkk̈onen, J.; Auriola, S.; Chilton, K.M.; Russell, R.G.G. Molecular mechanisms of action of bisphosphonates. Bone. 1999, 24, 73S–79S.
|
[14] |
Ansari, N.; Sims, N.A. The cells of bone and their interactions. Handb. Exp. Pharmacol. 2020, 262, 1–25.
|
[15] |
Hirabayashi, H.; Fujisaki, J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 2003, 42, 1319–1330.
|
[16] |
Buffo, L.; Rossini, M.; Buoncristiano, A.; Girardello, S.; Zamberlan, N.; Diani, F.; Adami, S. I bisfosfonati: un'alternativa al trattamento estrogenico nell'osteoporosi postmenopausale. Esperienza con alendronato [Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate. Minerva. Ginecol. 1996, 48, 263–272.
|
[17] |
Chen, L.R.; Ko, N.Y.; Chen, K.H. Medical treatment for osteoporosis: from molecular to clinical opinions. Int. J. Mol. Sci. 2019, 20, 2213.
|
[18] |
Anesi, Generali, Sandoni, Pozzi, Grande. From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights. Int. J. Mol. Sci. 2019, 20, 4925.
|
[19] |
Rogers, M.J.; Mönkkönen, J.; Munoz, M.A. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, 139, 115493.
|
[20] |
Zameer, S.; Najmi, A.K.; Vohora, D.; Akhtar, M. Bisphosphonates: Future perspective for neurological disorders. Pharmacol. Rep. 2018, 70, 900–907.
|
[21] |
Wahl, O.; Holzgrabe, U. Impurity profiling of ibandronate sodium by HPLC-CAD. J. Pharm. Biomed. Anal. 2015, 114, 254–264.
|
[22] |
Schoener, C.A.; Curtis-Fisk, J.L.; Rogers, T.L.; Tate, M.P. High throughput research and evaporation rate modeling for solvent screening for ethylcellulose barrier membranes in pharmaceutical applications. Drug Dev. Ind. Pharm. 2016, 42, 1700–1707.
|
[23] |
Nazari, M.; Davoodabadi, A.; Huang, D.Z.; Luo, T.F.; Ghasemi, H. On interfacial viscosity in nanochannels. Nanoscale. 2020, 12, 14626–14635.
|
[24] |
PK, R.; Sankaran, B.P. Tay-Sachs disease. 2020 nov 17. in: StatPearls [Internet]. treasure island (FL): StatPearls publishing; 2021 jan-. PMID: 33232090. 2020. 11.
|
[25] |
Figueroa, I.A.; Coates, J.D. Microbial phosphite oxidation and its potential role in the global phosphorus and carbon cycles. Adv. Appl. Microbiol. 2017, 98, 93–117.
|
[26] |
Wang, X.D.; Liang, T.Z.; Zhu, Y.X.; Qiu, J.C.; Qiu, X.J.; Lian, C.J.; Gao, B.; Peng, Y.; Liang, A.J.; Zhou, H.; Yang, X.M.; Liao, Z.H.; Li, Y.Y.; Xu, C.X.; Su, P.Q.; Huang, D.S. Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis. Mol. Med. Camb. Mass. 2019, 25, 43.
|
[27] |
Oršolić, N.; Nemrava, J.; Jeleč, Ž.; Kukolj, M.; Odeh, D.; Terzić, S.; Fureš, R.; Bagatin, T.; Bagatin, D. The beneficial effect of proanthocyanidins and icariin on biochemical markers of bone turnover in rats. Int. J. Mol. Sci. 2018, 19, 2746.
|
[1] | Min Wan, Jinyu Liu, Guangyi Yu, Suiju Tong, Lei Ke, Yu Zhang, Ruxu You. Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 417-425. |
[2] | Feng Zhao, Rui Wang, Hongxiong Zhang, Taixiang Gao, Nan Wang. Pharmacodynamics of Yuebi Jiazhu Decoction on renal protection of adriamycin nephropathy rats [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(9): 711-717. |
[3] | Tao Gao, Lei Liu, Yan Wu, Quan Du. Preclinical safety evaluation of WangShiBaoChiWan [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(1): 31-46. |
[4] | Mengqiu Lu, Haizhen Liang, Pengfei Tu, Yong Jiang. Pharmacodynamic comparison of two different source plants of Murrayae Folium et Cacumen [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 49-57. |
[5] | Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma. Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 729-733. |
[6] | Fang Wang, Zhuo Chen, Lin Li, Mingzhi Zhu, Youyi Xiong, Yuanting Gu. Pharmacokinetically determined docetaxel exposure as a predictor of hematologic toxicity in Chinese patients with early stage breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 512-516. |
[7] | Cynthia Astiti Putri, I Gusti Agung Ayu Kartika, I Ketut Adnyana. Preventive effect of Peperomia pellucida (L.) Kunth herbs on ovariectomy-induced osteoporotic rats [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 546-551. |
[8] | Yi-Bo Wang, Jian-Cheng Wang*, Meng Meng, Hua Zhang, Qiang Zhang . Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration [J]. , 2010, 19(3): 214-222. |
[9] | Xin-Ru Li, Yan-Qing Huang, Xiao-Yan Li, Yan-Xia Zhou, Yan Liu*, Ming Guo, Qing-Fen Zhu, Yuan-Chao Xie, Zhi-Yun Fan. Preparation and evaluation of sinomenine hydrochloride patch [J]. , 2010, 19(2): 110-114. |
[10] | ZHANG Xuan, ZHANG Hua, WANG Gui-ling, ZHANG Da-wei, WANG Jing, LIN Wei, ZHANG Qiang*. Hypoglycemic Effect of Intravenous Polyethylene Glycol-Coated Liposomal Insulin on Normal Rats [J]. , 2004, 13(1): 28-31. |
[11] | Dong Mei, Feng Fengyi*, Fu Qiang, Zhu Zhu. Study on Pharmacokinetics and Pharmacodynamics of High Dose Epirubicin in Cancer Patients [J]. , 2000, 9(2): 92-95. |
[12] | Zhen-Li Lin, Xiang-Lan Zhao. Pharmacokinetics and Pharmacodynamics of Nitrendipine [J]. , 1994, 3(2): 173-175. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||